Genolution（A225220）株式概要ジェノリューション社は韓国内外で体外診断用医薬品を製造販売している。 詳細A225220 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6報酬過去 1 年間で収益は31.8%増加しましたリスク分析意味のある時価総額がありません ( ₩33B )すべてのリスクチェックを見るA225220 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩1.80k19.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-12b38b2016201920222025202620282031Revenue ₩9.4bEarnings ₩1.2bAdvancedSet Fair ValueView all narrativesGenolution Inc. 競合他社DT&CROSymbol: KOSDAQ:A383930Market cap: ₩29.6bSLS BIOSymbol: KOSDAQ:A246250Market cap: ₩26.9bBioInfraSymbol: KOSDAQ:A199730Market cap: ₩17.4bWOOJUNG BIOSymbol: KOSDAQ:A215380Market cap: ₩45.6b価格と性能株価の高値、安値、推移の概要Genolution過去の株価現在の株価₩1,800.0052週高値₩3,015.0052週安値₩1,542.00ベータ0.131ヶ月の変化-8.86%3ヶ月変化-0.99%1年変化-22.41%3年間の変化-63.45%5年間の変化-72.87%IPOからの変化21.20%最新ニュースお知らせ • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South KoreaNew Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).最新情報をもっと見るRecent updatesお知らせ • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South KoreaNew Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).お知らせ • Jul 12Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years.Upcoming Dividend • Dec 21Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.お知らせ • Oct 06Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase.Upcoming Dividend • Sep 22Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years.Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years.お知らせ • Jun 09Genolution Inc. announced that it has received KRW 5 billion in fundingOn June 8, 2021, Genolution Inc. closed the transaction.お知らせ • Jun 05Genolution Inc. announced that it expects to receive KRW 5 billion in fundingGenolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years.分析記事 • Mar 17Could The Genolution Inc. (KOSDAQ:225220) Ownership Structure Tell Us Something Useful?If you want to know who really controls Genolution Inc. ( KOSDAQ:225220 ), then you'll have to look at the makeup of...Is New 90 Day High Low • Mar 10New 90-day low: ₩24,550The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: ₩24,800The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.Is New 90 Day High Low • Nov 24New 90-day low: ₩25,800The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.Is New 90 Day High Low • Nov 03New 90-day high: ₩43,600The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period.お知らせ • Jul 18Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 824,000 Price\Range: KRW 14000 Discount Per Security: KRW 840 Transaction Features: ESOP Related Offering株主還元A225220KR Life SciencesKR 市場7D4.3%-8.2%-8.2%1Y-22.4%-15.2%159.6%株主還元を見る業界別リターン: A225220過去 1 年間で-15.2 % の収益を上げたKR Life Sciences業界を下回りました。リターン対市場: A225220は、過去 1 年間で159.6 % のリターンを上げたKR市場を下回りました。価格変動Is A225220's price volatile compared to industry and market?A225220 volatilityA225220 Average Weekly Movement5.3%Life Sciences Industry Average Movement11.0%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%安定した株価: A225220 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A225220の 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2006n/aKi-Ok Kimgenolution.co.krジェノリューション社は韓国および海外で体外診断用医薬品の製造・販売を行っている。同社の製品は主に分子診断学、リボ核酸干渉（RNAi）サービス、繁殖・駆除予防のためのdsRNA研究に重点を置いている。同社は、様々なサンプルからDNAやRNAを単離する自動抽出システムNextractor、FFPE、全血、頬ぬぐい液、RV、TB/NTM、STD、HPV、HBV、CMV/EBV抽出キット、米、植物、細胞抽出キットを提供している。また、遺伝子発現を阻害するsiRNA/shRNA合成サービスやその他遺伝子関連サービス、様々な生体にRNAを注入して遺伝子発現を阻害する長鎖dsRNA合成サービスも提供している。同社は2006年に設立され、韓国のソウルに拠点を置く。もっと見るGenolution Inc. 基礎のまとめGenolution の収益と売上を時価総額と比較するとどうか。A225220 基礎統計学時価総額₩32.52b収益（TTM）-₩11.64b売上高(TTM)₩9.40b3.5xP/Sレシオ-2.8xPER（株価収益率A225220 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A225220 損益計算書（TTM）収益₩9.40b売上原価₩5.96b売上総利益₩3.44bその他の費用₩15.08b収益-₩11.64b直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-644.43グロス・マージン36.60%純利益率-123.80%有利子負債／自己資本比率35.2%A225220 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 03:56終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genolution Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
New Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).
お知らせ • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
New Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).
お知らせ • Jul 12Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years.
Upcoming Dividend • Dec 21Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.
お知らせ • Oct 06Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
Upcoming Dividend • Sep 22Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years.
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years.
お知らせ • Jun 09Genolution Inc. announced that it has received KRW 5 billion in fundingOn June 8, 2021, Genolution Inc. closed the transaction.
お知らせ • Jun 05Genolution Inc. announced that it expects to receive KRW 5 billion in fundingGenolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years.
分析記事 • Mar 17Could The Genolution Inc. (KOSDAQ:225220) Ownership Structure Tell Us Something Useful?If you want to know who really controls Genolution Inc. ( KOSDAQ:225220 ), then you'll have to look at the makeup of...
Is New 90 Day High Low • Mar 10New 90-day low: ₩24,550The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: ₩24,800The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.
Is New 90 Day High Low • Nov 24New 90-day low: ₩25,800The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Nov 03New 90-day high: ₩43,600The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period.
お知らせ • Jul 18Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 824,000 Price\Range: KRW 14000 Discount Per Security: KRW 840 Transaction Features: ESOP Related Offering
